Author: Vere Hodge, R Anthony
Title: Meeting report: 30th International Conference on Antiviral Research, in Atlanta, GA, USA Document date: 2018_6_28
ID: tudwns0r_27
Snippet: In summary, FMCA and its phosphoramidate prodrug, FMCA-P, were fully active against HBV strains resistant to lamivudine, entecavir, adefovir and tenofovir. FMCA appears to have a good safety profile, having minimal inhibitory effects on cellular and mitochondrial DNA replication. Compared to entecavir, the good safety profile enables higher doses of FMCA-P to be used in efficacy studies using a mouse model. Further in vivo evaluation of FMCA-P is.....
Document: In summary, FMCA and its phosphoramidate prodrug, FMCA-P, were fully active against HBV strains resistant to lamivudine, entecavir, adefovir and tenofovir. FMCA appears to have a good safety profile, having minimal inhibitory effects on cellular and mitochondrial DNA replication. Compared to entecavir, the good safety profile enables higher doses of FMCA-P to be used in efficacy studies using a mouse model. Further in vivo evaluation of FMCA-P is ongoing. Although pre-existing HBV cccDNA is not eliminated by therapy with nucleoside/tide analogues, such drugs will play a vital role in controlling HBV replication while minimising drug resistance.
Search related documents:
Co phrase search for related documents- dna replication and safety profile: 1
- dna replication and vital role: 1
- drug resistance and safety profile: 1, 2, 3, 4, 5
- drug resistance and vital role: 1, 2, 3
- efficacy study and safety profile: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- efficacy study and vital role: 1, 2, 3
- good safety and safety profile: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- good safety profile and safety profile: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- HBV replication and phosphoramidate prodrug: 1
- HBV replication and safety profile: 1
- HBV replication control and safety profile: 1
- high dose and safety profile: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19
- high dose and vital role: 1, 2
- high dose and vivo evaluation: 1
- inhibitory effect and safety profile: 1, 2, 3, 4, 5, 6, 7, 8
- inhibitory effect and vital role: 1, 2, 3, 4
- inhibitory effect and vivo evaluation: 1, 2, 3
- mouse model and vital role: 1, 2, 3, 4
- mouse model and vivo evaluation: 1, 2
Co phrase search for related documents, hyperlinks ordered by date